Kazumasa Nagayama
Representative Director and President

Moderna extends its heartfelt congratulations to Health and Global Policy Institute (HGPI) on its 20th anniversary.

Since our founding in 2010, Moderna has been committed to improving people’s health by advancing vaccines and therapeutics rooted in messenger RNA (mRNA) technology. In 2021, we established Moderna Japan, driven by our mission to “deliver the greatest possible impact to people through mRNA medicines.” Through our COVID-19 vaccine, we have strived to contribute to the health of people in Japan.

mRNA technology holds the potential to revolutionize how humanity combats disease. At Moderna, we are actively conducting research and development across various fields, including infectious diseases, rare diseases, cardiovascular conditions, autoimmune disorders, and cancer treatment. We believe that this technology can offer new solutions for medical challenges that have historically been difficult to address. Inspired by HGPI’s expertise and proactive approach, we are honored to continue tackling global challenges together.

Congratulations once again on HGPI’s 20th anniversary. We sincerely wish you continued success and further accomplishments in the years to come.

　■Company information
　Moderna, Inc.
　https://www.modernatx.com/en-US